We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-12.61%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.9B
AUM Growth
-$300M
Cap. Flow
+$226M
Cap. Flow %
7.79%
Top 10 Hldgs %
60.65%
Holding
101
New
14
Increased
15
Reduced
4
Closed
21

Top Buys

1
SGEN
Seagen Inc. Common Stock
SGEN
+$145M
2
ARVN icon
Arvinas
ARVN
+$81.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$58.7M
4
RVMD icon
Revolution Medicines
RVMD
+$58.5M
5
ALLO icon
Allogene Therapeutics
ALLO
+$39.8M

Top Sells

1
RCUS icon
Arcus Biosciences
RCUS
+$103M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$41.2M
3
PCVX icon
Vaxcyte
PCVX
+$31.5M
4
BCYC
Bicycle Therapeutics
BCYC
+$24M
5
EXEL icon
Exelixis
EXEL
+$19.6M

Sector Composition

1 Healthcare 98.48%
2 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRNX icon
26
Crinetics Pharmaceuticals
CRNX
$8.88B
$24.8M 0.86%
1,330,263
+540,054
+68% +$10.8M
GERN icon
27
Geron
GERN
$924M
$22M 0.76%
14,168,988
-116,726
-0.8% -$165K
ARQT icon
28
Arcutis Biotherapeutics
ARQT
$3.55B
$19.1M 0.66%
895,503
– –
EWTX icon
29
Edgewise Therapeutics
EWTX
$4.3B
$18.8M 0.65%
2,359,808
– –
JANX icon
30
Janux Therapeutics
JANX
$995M
$17.4M 0.6%
1,421,319
– –
VTYX
31
DELISTED
Ventyx Biosciences
VTYX
$15.9M 0.55%
1,300,000
– –
EXEL icon
32
CALL
Exelixis
EXEL
$14B
$15.8M 0.55%
+760,000
New +$15.7M
ORIC icon
33
Oric Pharmaceuticals
ORIC
$1.12B
$15.3M 0.53%
3,418,068
– –
CGEM icon
34
Cullinan Oncology
CGEM
$1.08B
$15M 0.52%
+1,169,889
New +$13.3M
INCY icon
35
Incyte
INCY
$23.5B
$13.9M 0.48%
+182,783
New +$13.9M
OVID icon
36
Ovid Therapeutics
OVID
$455M
$13.2M 0.45%
6,117,400
– –
KDNY
37
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$12.1M 0.42%
690,000
– –
GRCL
38
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$10.6M 0.36%
1,921,310
+361,600
+23% +$1.12M
TNGX icon
39
Tango Therapeutics
TNGX
$4.68B
$10.4M 0.36%
2,302,065
+1,540,094
+202% +$9.32M
AKUS
40
DELISTED
Akouos Inc
AKUS
$9.27M 0.32%
1,975,984
– –
HOOK
41
DELISTED
HOOKIPA Pharma
HOOK
$8.15M 0.28%
500,000
– –
DTIL icon
42
Precision BioSciences
DTIL
$205M
$8.06M 0.28%
+167,866
New +$9.85M
SURF
43
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$7.63M 0.26%
4,653,000
– –
NGM
44
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$6.94M 0.24%
541,108
– –
FLAC
45
DELISTED
Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares
FLAC
$5.8M 0.2%
587,615
– –
ITOS
46
DELISTED
iTeos Therapeutics
ITOS
$5.77M 0.2%
279,999
+207,178
+285% +$4.92M
JYAC
47
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.94M 0.17%
500,000
– –
ALGS icon
48
Aligos Therapeutics
ALGS
$35.2M
$4.78M 0.16%
157,934
– –
RNAC icon
49
Cartesian Therapeutics
RNAC
$247M
$4.58M 0.16%
+116,667
New +$3.46M
AVEO
50
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$4.25M 0.15%
+647,489
New +$3.14M
1
2
3 4 5

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q2 2022 Portfolio in Review

As of Q2 2022, EcoR1 Capital held 101 positions worth $2.9B, down 9.4% from $3.2B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital deployed $226M of net new capital in Q2 2022, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 1,008,628 shares worth $178M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Alector, an estimated $16.8M trimmed.

  • EcoR1 Capital's largest Q2 2022 buy was Seagen Inc. Common Stock: 1,008,628 shares worth $178M.
  • EcoR1 Capital added most to Arvinas in Q2 2022, an estimated $81.3M increase.
  • EcoR1 Capital's biggest Q2 2022 reduction was Alector, cutting an estimated $16.8M.
  • EcoR1 Capital fully exited Arcus Biosciences in Q2 2022, selling an estimated $103M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $2.9B portfolio in Q2 2022.
  • EcoR1 Capital opened 14 new positions and closed 21 in Q2 2022.
  • EcoR1 Capital's portfolio value fell 9.4% quarter-over-quarter to $2.9B.

Based on EcoR1 Capital's 13F filing for Q2 2022, filed 15 Aug 2022.